Daptomycin

Generic Name
Daptomycin
Brand Names
Cubicin, Dapzura, Daptomycin Hospira
Drug Type
Small Molecule
Chemical Formula
C72H101N17O26
CAS Number
103060-53-3
Unique Ingredient Identifier
NWQ5N31VKK
Background

Daptomycin is a cyclic lipopeptide antibacterial agent with a broad spectrum of activity against Gram-positive bacteria, including methicillin-susceptible and -resistant Staphylococcus aureus (MSSA/MRSA) and vancomycin-resistant Enterococci (VRE). Chemically, daptomycin comprises 13 amino acids, including several non-standard and D-amino acids, with the C-te...

Indication

Daptomycin is indicated for the treatment of complicated skin and skin structure infections (cSSSI) in patients one year of age and older. It is also indicated for the treatment of Staphylococcus aureus bloodstream infections (bacteremia) in patients one year of age and older, including in adult patients with right-sided infective endocarditis.
...

Associated Conditions
Complicated Skin and Skin Structure Infection, Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)
Associated Therapies
-
Clinical Trials
Related News

Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients

First Posted Date
2012-11-28
Last Posted Date
2023-05-03
Lead Sponsor
Henry Ford Health System
Target Recruit Count
100
Registration Number
NCT01734694
Locations
🇺🇸

Henry Ford Hospital, Detroit, Michigan, United States

Safety & Efficacy of Daptomycin Versus Standard of Care (SOC) in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)

Phase 4
Completed
Conditions
Bacteremia
Interventions
Drug: Comparator
Drug: Daptomycin
First Posted Date
2012-11-19
Last Posted Date
2018-08-28
Lead Sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Target Recruit Count
82
Registration Number
NCT01728376

The Effects of Daptomycin and Cytokines Production in Comparison With Vancomycin

Phase 4
Completed
Conditions
Cellulitis
Interventions
Drug: Daptomycin
Drug: Vancomycin
First Posted Date
2012-06-22
Last Posted Date
2015-03-20
Lead Sponsor
Hospital Universitario Evangelico de Curitiba
Target Recruit Count
20
Registration Number
NCT01626560
Locations
🇧🇷

Hospital Universitário Evangelico de Curitiba, Curitiba, Parana, Brazil

Evaluation of Daptomycin for the Emergency Department Treatment of Complicated Skin and Skin Structure Infections

Phase 4
Completed
Conditions
Cellulitis
Skin Infections
Interventions
Drug: Vancomycin
Drug: Daptomycin
First Posted Date
2012-03-09
Last Posted Date
2014-08-01
Lead Sponsor
University of Cincinnati
Target Recruit Count
104
Registration Number
NCT01549613
Locations
🇺🇸

University of Cincinnati, Dept. of Emergency Medicine, Cincinnati, Ohio, United States

Daptomycin in Pediatric Patients With Bacterial Meningitis

Phase 1
Terminated
Conditions
Meningitis
Interventions
Drug: Daptomycin
First Posted Date
2012-01-31
Last Posted Date
2018-10-11
Lead Sponsor
Insel Gruppe AG, University Hospital Bern
Target Recruit Count
1
Registration Number
NCT01522105
Locations
🇨🇭

Dep. of Pediatrics, University Hospital Bern, Bern, Switzerland

Daptomycin Versus Vancomycin in Participants With Skin Infections Due to MRSA

First Posted Date
2011-08-18
Last Posted Date
2018-09-05
Lead Sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Target Recruit Count
250
Registration Number
NCT01419184

Vancomycin Versus Daptomycin for the Treatment of Methicillin-resistant Staphylococcus Aureus Bacteremia Due to Isolates With High Vancomycin Minimum Inhibitory Concentrations (MICs)

Phase 4
Terminated
Conditions
Bacteremia
Interventions
Drug: Daptomycin
Drug: Vancomycin
First Posted Date
2011-02-01
Last Posted Date
2014-02-10
Lead Sponsor
St. John Health System, Michigan
Target Recruit Count
11
Registration Number
NCT01287832

Daptomycin Versus Placebo in Patients With Neutropenia and Fever

Phase 3
Terminated
Conditions
Febrile Neutropenia
Interventions
Other: Saline Placebo
Drug: Daptomycin
First Posted Date
2010-10-07
Last Posted Date
2014-04-10
Lead Sponsor
University of Rochester
Target Recruit Count
36
Registration Number
NCT01216241
Locations
🇺🇸

University of Rochester Medical Center, Rochester, New York, United States

Daptomycin Pharmacokinetics in Critically Ill Patients Undergoing Continuous Veno-venous Hemodiafiltration, a Dose Finding Study

First Posted Date
2010-09-30
Last Posted Date
2010-10-18
Lead Sponsor
University of Zurich
Target Recruit Count
15
Registration Number
NCT01212432

Initial Treatment for Acute Bacterial Skin Infections (ABSSSI) Caused by Staphylococcus Aureus

First Posted Date
2010-09-29
Last Posted Date
2012-05-17
Lead Sponsor
PolyMedix, Inc.
Target Recruit Count
215
Registration Number
NCT01211470
Locations
🇷🇺

11 Sites, Multiple, Russian Federation

🇺🇦

5 Sites, Multiple, Ukraine

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy